Medical Health & Life Science Research News

Report explores the North America leukemia therapeutics industry

Report explores the North America leukemia therapeutics industry

North America Leukemia Therapeutics Industry by disease condition (chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia, acute myeloid leukemia), by diagnosis (CT scan, biopsy, MRI), by treatments (chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant, stem cell therapy), by drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

- Advertising -

According to the report North America Leukemia Therapeutics Industry, published by Market Data Forecast, The Industry has been estimated at USD 1.85 Billion in 2016 and is projected to reach USD 2.83 Billion by 2021, at a CAGR of 8.9% during the forecast period from 2016 to 2021. 

Leukemia is the cancer of the WBC or the bone marrow, which occurs due to abnormal increase in the count of white blood cells. It is identified by the type of the blood cell that is affected (lymphocytic or myelocytic) and by the spread of the diseases (either acute or chronic).

It accounts for almost 0.0148% of all the men and 0.009% of all the women worldwide.

- Advertising -

Browse Market data tables and in-depth TOC of the North America Leukemia TherapeuticsIndustry to 2021 at www.marketdataforecast.com/market-…utics-market-823/

The North American Industry for Leukemia Therapeutics is mainly increasing due to increasing occurrence of leukemia. there is raise in awareness regarding the disease, drugs and treatments due to increasing involvement of R&D in coming up with new ways of treatments and drugs.

Due to this, the Industry is highly driven. But due to high cost of treatment and drugs, there is a chance of drop in the Industry growth.

North America Industry for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the Industry is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia.

By diagnosis, the Industry is further sub-segmented into CT scan, biopsy and MRI. By treatments, the Industry is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy.

By drugs, the Industry is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic Industry owing to high prevalence rate.

Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic Industry. Gleevec was the one of the major Industry growth contributors, in the drugs category.

www.marketdataforecast.com/market-…23/request-sample

Geographically, North America Industry for Leukemia Therapeutics is segmented into U.S.A and Canada. North America holds the largest share in global Industry, followed by Europe.

A number of factors such as rising prevalence of leukemia, and increasing penetration of companies into the Industry with increasing R&D involvement are creating opportunities for Industry growth in Leukemia Therapeutics Industry in the North American region.

Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.

are the major players of North America Leukemia Therapeutics Industry.

Report: www.marketdataforecast.com/market-…arket-823/inquire

Key Points from Table of Contents

Overview                                                       

  • Executive Summary                                
  • Key Inferences                                         
  • New Developments                               

Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                    

North America Leukemia Therapeutics Industry: Segmentation

  • By Disease Condition                          
  • o Chronic Lymphatic Leukemia         
  • o Acute Lymphatic Leukemia             
  • o Chronic Myeloid Leukemia             
  • o Acute Myeloid Leukemia  
  • By Diagnosis                           
  • o CT scan    
  • o Biopsy      
  • o MRI          
  • By Treatments                        
  • o Chemotherapy     
  • o Radiation therapy
  • o Immunotherapy  
  • o Surgery    
  • o Targeted Therapy
  • o Bone marrow transplant  
  • o Stem Cell Therapy
  • By Drugs                    
  • o Gleevec    
  • o Sapacitabine         
  • o GA101      
  • o Vasaroxine            
  • o Tosedosat             

Geographical Analysis                                                              

  • United States                            
  • Canada      

Strategic Analysis                                                       

  • PESTLE analysis                                                                       
  • Porter’s Five analysis                                              

Industry Leaders' Analysis                                                        

Competitive Landscape                                                           

www.marketdataforecast.com/market-…/request-discount

 

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...